GlassScriptPhysician profile
Morgan Elyse Foster
NPI 1518675347
$3,193.20
in general payments reported to CMS, 2019-2025
17 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,208 · 2024: $1,378 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,189 · Education: $3.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,189.41 |
| Education | $3.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,059.54 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $412.37 | 2024-2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $326.94 | 2023-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $285.61 | 2023-2025 | Aristada, Lybalvi |
| Corium, LLC | $186.97 | 2023-2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.95 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $163.58 | 2023 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $146.38 | 2023-2025 | Trintellix |
| Axsome Therapeutics, INC. | $123.73 | 2024-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $93.44 | 2024 | |
| Neos Therapeutics, LP | $65.36 | 2023-2024 | Adzenys Xr-Odt |
| Lundbeck LLC | $39.76 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $30.77 | 2023-2024 | Quviviq |
| Tris Pharma INC | $22.73 | 2023 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $21.80 | 2025 | Jornay Pm |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $20.62 | 2023 | Ingrezza |
| Aytu Biopharma, INC. | $14.65 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.